Identification

Name
Carisoprodol
Accession Number
DB00395  (APRD00417)
Type
Small Molecule
Groups
Approved
Description

A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202)

Structure
Thumb
Synonyms
  • (+-)-2-Methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate
  • (1-Methylethyl)carbamic acid 2-(((aminocarbonyl)oxy)methyl)-2-methylpentyl ester
  • (RS)-2-{[(aminocarbonyl)oxy]methyl}-2-methylpentyl isopropylcarbamate
  • 2-Methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate
  • 2-Methyl-2-propyltrimethylene carbamate isopropylcarbamate
  • Carbamic acid 2-isopropylcarbamoyloxymethyl-2-methyl-pentyl ester
  • Carisoprodate
  • Carisoprodol
  • Carisoprodolum
  • Isobamate
  • Isomeprobamate
  • Isopropyl meprobamate
  • Isopropylmeprobamate
  • N-Isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamate
  • Someprobamate
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CarisoprodolTablet350 mg/1OralVintage Pharmaceuticals, LLC2007-08-022007-08-02Us
SomaTablet250 mg/1OralMEDA Pharmaceuticals2007-09-01Not applicableUs0037 225020180814 13942 8q2csu
SomaTablet250 mg/1OralStat Rx USA2007-09-01Not applicableUs00037 2250 10 nlmimage10 bd1d5efa
SomaTablet250 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2007-09-012015-01-01Us
SomaTablet350 mg/1OralMEDA Pharmaceuticals1959-07-01Not applicableUs
SomaTablet250 mg/1OralRebel Distributors2007-09-01Not applicableUs
SomaTablet350 mg/1OralPhysicians Total Care, Inc.1994-10-042008-05-05Us
Soma Tablets 350mgTablet350 mgOralCarter Horner Corp.1962-12-312003-03-14Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CarisoprodolTablet350 mg/1OralMylan Institutional2012-01-112015-03-31Us
CarisoprodolTablet350 mg/1OralMutual Pharmaceutical1991-10-17Not applicableUs
CarisoprodolTablet350 mg/1OralRed Pharm Drug, Inc.1997-09-08Not applicableUs
CarisoprodolTablet250 mg/1OralAurobindo Pharma Limited2016-11-08Not applicableUs
CarisoprodolTablet350 mg/1OralWest Ward Pharmaceutical1996-01-24Not applicableUs
CarisoprodolTablet250 mg/1OralNostrum Laboratories, Inc.2017-05-11Not applicableUs
CarisoprodolTablet350 mg/1OralNucare Pharmaceuticals, Inc.2010-07-01Not applicableUs
CarisoprodolTablet350 mg/1OralProficient Rx LP2015-06-01Not applicableUs
CarisoprodolTablet350 mg/1OralProficient Rx LP2014-06-01Not applicableUs
CarisoprodolTablet350 mg/1OralAidarex Pharmaceuticals LLC2015-06-01Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Carisoprodol and AspirinCarisoprodol (200 mg/1) + Acetylsalicylic acid (325 mg/1)TabletOralActavis Totowa LLC1998-01-012008-06-20Us
Carisoprodol and AspirinCarisoprodol (200 mg/1) + Acetylsalicylic acid (325 mg/1)TabletOralEon Labs, Inc.1996-04-252020-02-29Us
Carisoprodol and AspirinCarisoprodol (200 mg/1) + Acetylsalicylic acid (325 mg/1)TabletOralHeritage2011-03-31Not applicableUs
Carisoprodol and AspirinCarisoprodol (200 mg/1) + Acetylsalicylic acid (325 mg/1)TabletOralPhysicians Total Care, Inc.1992-01-142011-06-30Us
Carisoprodol and AspirinCarisoprodol (200 mg/1) + Acetylsalicylic acid (325 mg/1)TabletOralIngenus Pharmaceuticals Nj, Llc2011-06-09Not applicableUs
CARISOPRODOL and ASPIRINCarisoprodol (200 mg/1) + Acetylsalicylic acid (325 mg/1)TabletOralRising Pharmaceuticals2010-01-07Not applicableUs
Carisoprodol and AspirinCarisoprodol (200 mg/1) + Acetylsalicylic acid (325 mg/1)TabletOralPar Pharmaceutical1989-03-312012-11-30Us
Carisoprodol and AspirinCarisoprodol (200 mg/1) + Acetylsalicylic acid (325 mg/1)TabletOralRebel Distributors2009-10-01Not applicableUs
Carisoprodol and AspirinCarisoprodol (200 mg/1) + Acetylsalicylic acid (325 mg/1)TabletOralApotheca, Inc.2009-10-012011-01-20Us
Carisoprodol, Aspirin and Codeine PhosphateCarisoprodol (200 mg/1) + Acetylsalicylic acid (325 mg/1) + Codeine phosphate hemihydrate (16 mg/1)TabletOralEon Labs, Inc.1996-04-162019-09-30Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
PrazolamineCarisoprodol (350 mg/1) + gamma-Aminobutyric acid (100 mg/1)KitPhysician Therapeutics Llc2011-07-07Not applicableUs
International/Other Brands
Carisoma / Gencari (Genovate) / Genesafe (Genovate) / Hiranin (Hwang's) / Listaflex (Finadiet) / Sanoma / Tensaprin (Newport)
Categories
UNII
21925K482H
CAS number
78-44-4
Weight
Average: 260.33
Monoisotopic: 260.173607266
Chemical Formula
C12H24N2O4
InChI Key
OFZCIYFFPZCNJE-UHFFFAOYSA-N
InChI
InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)
IUPAC Name
2-[(carbamoyloxy)methyl]-2-methylpentyl N-(propan-2-yl)carbamate
SMILES
CCCC(C)(COC(N)=O)COC(=O)NC(C)C

Pharmacology

Indication

For the relief of discomfort associated with acute, painful, musculoskeletal conditions.

Associated Conditions
Pharmacodynamics

Carisoprodol is used as a skeletal muscle relaxant. One of its metabolites, meprobamate, is available as an anxiolytic agent.

Mechanism of action

Carisoprodol is a central nervous system depressant that acts as a sedative and skeletal muscle relaxant. Rather than acting directly on skeletal muscle, carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. Its exact mechanism of action is not yet known.

TargetActionsOrganism
UGamma-aminobutyric acid receptor subunit alpha-1Not AvailableHuman
UGamma-aminobutyric acid receptor subunit beta-2Not AvailableHuman
UGamma-aminobutyric acid receptor subunit gamma-2Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

60%

Metabolism

Hepatic. Metabolized in the liver via the cytochrome P450 oxidase isozyme CYP2C19.

Route of elimination

Carisoprodol is eliminated by both renal and non-renal routes.

Half life

8 hours

Clearance
  • oral cl=0.772 L/hour/kg [Women]
  • oral cl=0.38 L/hour/kg [Men]
Toxicity

Symptoms of overdose include drowsiness, giddiness, nausea, indigestion, or rash. Other adverse effects attributed to therapeutic use of carisoprodol include dizziness, irritability, insomnia, diplopia, temporary loss of vision, ataxia, weakness, headache, and dysarthria. Non-CNS adverse effects include gastrointestinal complaints, tachycardia, and postural hypotension. Patients sensitive to sulfites or tartrazine may experience wheezing, allergic rashes including erythema multiforme, or anaphylaxis after using some preparations of carisoprodol which contain such additives

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C19CYP2C19*2ANot Available681G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*2BNot Available681G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*3Not Available636G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*4Not Available1A>GEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*5Not Available1297C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*6Not Available395G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*7Not Available19294T>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*22Not Available557G>C / 991A>GEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*24Not Available99C>T / 991A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2C19CYP2C19*35Not Available12662A>GEffect InferredPoor drug metabolizer.Details

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Carisoprodol.
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Carisoprodol.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with 3,4-Methylenedioxyamphetamine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Carisoprodol is combined with 7-Nitroindazole.
AbataceptThe metabolism of Carisoprodol can be increased when combined with Abatacept.
AbirateroneThe metabolism of Carisoprodol can be decreased when combined with Abiraterone.
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

References

Synthesis Reference

Berger, F.M. and Ludwig, B.J.; U S . Patent 2,937,119; May 17,1960; assigned to Carter Products, Inc.

General References
  1. Toth PP, Urtis J: Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther. 2004 Sep;26(9):1355-67. [PubMed:15530999]
  2. Chou R, Peterson K, Helfand M: Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004 Aug;28(2):140-75. [PubMed:15276195]
  3. Littrell RA, Hayes LR, Stillner V: Carisoprodol (Soma): a new and cautious perspective on an old agent. South Med J. 1993 Jul;86(7):753-6. [PubMed:8322081]
External Links
Human Metabolome Database
HMDB0014539
KEGG Drug
D00768
KEGG Compound
C07927
PubChem Compound
2576
PubChem Substance
46506377
ChemSpider
2478
ChEBI
3419
ChEMBL
CHEMBL1233
PharmGKB
PA448809
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Carisoprodol
ATC Codes
M03BA52 — Carisoprodol, combinations excl. psycholepticsM03BA02 — CarisoprodolM03BA72 — Carisoprodol, combinations with psycholeptics
FDA label
Download (84.9 KB)
MSDS
Download (73.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentBack Pain Lower Back1

Pharmacoeconomics

Manufacturers
  • Meda pharmaceuticals meda pharmaceuticals inc
  • Able laboratories inc
  • Actavis totowa llc
  • Advent pharmaceuticals inc
  • Aurobindo pharma ltd
  • Concord laboratories inc
  • Corepharma llc
  • Mutual pharmaceutical co inc
  • Pioneer pharmaceuticals inc
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Schering corp sub schering plough corp
Packagers
  • Aidarex Pharmacuticals LLC
  • Amerisource Health Services Corp.
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Aurobindo Pharma Ltd.
  • Blenheim Pharmacal
  • Bryant Ranch Prepack
  • Cardinal Health
  • Carlisle Laboratories Inc.
  • Chattem Chemicals Inc.
  • Corepharma LLC
  • Darby Dental Supply Co. Inc.
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Duramed
  • Eon Labs
  • Gm Pharmaceuticals Inc.
  • H and H Laboratories
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Innoviant Pharmacy Inc.
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Meda AB
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescription Dispensing Service Inc.
  • Qualitest
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Sandhills Packaging Inc.
  • Sandoz
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Sun Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Vintage Pharmaceuticals Inc.
  • Vision Pharma LLC
  • Wallace Pharmaceuticals Inc.
  • Watson Pharmaceuticals
  • West-Ward Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral350 mg/1
TabletOral
Kit
TabletOral250 mg/1
Tablet, film coatedOral350 mg/1
TabletOral350 mg
Prices
Unit descriptionCostUnit
Soma 350 mg tablet5.75USD tablet
Soma Compound 200-325 mg tablet4.58USD tablet
Soma 250 mg tablet3.24USD tablet
Carisoprodol powder1.17USD g
Carisoprodol 350 mg tablet0.57USD tablet
Flexall plus gel0.08USD g
Flexall 16% gel0.06USD g
Flexall 7% gel0.05USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)89-91Berger, F.M. and Ludwig, B.J.; U S . Patent 2,937,119; May 17,1960; assigned to Carter Products, Inc.
water solubility300 mg/L (at 25 °C)MERCK INDEX (1996)
logP2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.792 mg/mLALOGPS
logP1.76ALOGPS
logP1.92ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)15.06ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area90.65 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity67.1 m3·mol-1ChemAxon
Polarizability28.77 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9626
Blood Brain Barrier+0.9679
Caco-2 permeable-0.5533
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.8014
P-glycoprotein inhibitor IINon-inhibitor0.8381
Renal organic cation transporterNon-inhibitor0.9519
CYP450 2C9 substrateNon-substrate0.9041
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6418
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8659
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6872
BiodegradationNot ready biodegradable0.973
Rat acute toxicity2.3261 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9957
hERG inhibition (predictor II)Non-inhibitor0.9362
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0a4i-9200000000-7ee2bc67a583d40d99b8
Mass Spectrum (Electron Ionization)MSsplash10-0a4l-9200000000-84ceb4ca447a62939b63
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-4910000000-0fe5eef3c39360c36d38
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01ot-9300000000-94d7b1adea0d831c0950
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03dj-9100000000-a99d65f53726ca3b6116
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-9000000000-618eb5a23da29ec51cb6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-9000000000-d2d07fc2a5972fd4e9f8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-9000000000-007521fa65c254bad2b6
MS/MS Spectrum - , positiveLC-MS/MSsplash10-056r-1920000000-df362ad4c912b7d0fb43

Taxonomy

Description
This compound belongs to the class of organic compounds known as carbamate esters. These are compounds containing an ester of carbamic acid with the general structure R2NC(=O)OR' (R' not H). They are esters of carbamic acids.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Carbamate esters
Alternative Parents
Organic carbonic acids and derivatives / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Carbamic acid ester / Carbonic acid derivative / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative / Organooxygen compound / Organonitrogen compound / Carbonyl group
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
carbamate ester (CHEBI:3419)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB2
Uniprot ID
P47870
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-2
Molecular Weight
59149.895 Da
References
  1. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRG2
Uniprot ID
P18507
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-2
Molecular Weight
54161.78 Da
References
  1. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Bramness JG, Skurtveit S, Fauske L, Grung M, Molven A, Morland J, Steen VM: Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics. 2003 Jul;13(7):383-8. doi: 10.1097/01.fpc.0000054098.48725.88. [PubMed:12835613]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on June 13, 2005 07:24 / Updated on December 14, 2018 16:24